Wellington Management Group
SPRY icon

Wellington Management Group’s ARS Pharmaceuticals SPRY Stock Holding History

Wellington Management Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,433,187
Closed -$25M – 2098
2025
Q2 		$25M Buy
1,433,187
+1,301,411
+988% +$18.8M ﹤0.01% 888
2025
Q1 		$1.66M Sell
131,776
-31,476
-19% -$379K ﹤0.01% 1598
2024
Q4 		$1.72M Buy
163,252
+917
+0.6% +$12.8K ﹤0.01% 1605
2024
Q3 		$2.35M Buy
162,335
+45,452
+39% +$541K ﹤0.01% 1509
2024
Q2 		$995K Buy
116,883
+3,678
+3% +$32.6K ﹤0.01% 1678
2024
Q1 		$1.16M Buy
+113,205
New +$844K ﹤0.01% 1656
2021
Q1 		– Sell
-13,837
Closed -$641K – 2178
2020
Q4 		$641K Buy
+13,837
New +$462K ﹤0.01% 1678

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group's SPRY Position: Q3 2025 in Review

Wellington Management Group sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 1,433,187 shares — an estimated $25M sold.

Wellington Management Group first reported a position in SPRY in Q4 2020 and held it in 7 quarters. The position peaked at $25M in Q2 2025. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

  • Wellington Management Group reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Wellington Management Group sold 1,433,187 ARS Pharmaceuticals shares in Q3 2025, an estimated $25M.
  • Wellington Management Group first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 7 quarters.
  • Wellington Management Group's ARS Pharmaceuticals position peaked at $25M in Q2 2025.
  • 188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on Wellington Management Group's 13F filing for Q3 2025, filed 14 Nov 2025.